Artiva Biotherapeutics (ARTV) Total Non-Current Liabilities (2023 - 2024)

Artiva Biotherapeutics (ARTV) posted quarterly Total Non-Current Liabilities of $22.9 million for Q4 2024, down 54.85% year-over-year from $50.6 million in Q1 2024, and down 6.77% quarter-over-quarter from $24.5 million in Q3 2024.

Artiva Biotherapeutics (ARTV) Total Non-Current Liabilities (2023 - 2024) Analysis & Trends

Artiva Biotherapeutics (ARTV) has reported Total Non-Current Liabilities for 2 consecutive years, with $22.9 million the latest figure, recorded in Q4 2024.

  • In Q4 2024, Total Non-Current Liabilities fell 54.85% year-over-year to $22.9 million; the TTM figure through Dec 2024 stood at $22.9 million (down 54.85% YoY), while the FY2024 annual figure was $22.9 million, down 54.85% from the prior year.
  • Total Non-Current Liabilities retreated to $22.9 million in Q4 2024 per ARTV's latest filing, from $24.5 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $50.6 million in Q4 2023 and bottomed at $22.9 million in Q4 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 5.92 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 7.74 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 40.00 Mn
4 Revolution Medicines 43.64 Bn 43.64 Bn - 1.53 Bn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 1.88 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - 9.32 Bn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 4.20 Bn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 1.17 Bn
10 Artiva Biotherapeutics 451.28 Mn 451.28 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2024 22.87 Mn
Sep 30, 2024 24.53 Mn
Jun 30, 2024 50.52 Mn
Dec 31, 2023 50.64 Mn